Nucleotide sequences of regions of the envelope (env) and polymerase (po/) genes of human immunodeficiency virus type 1 (HIV-1) proviral DNA were obtained from sequential blood and autopsy samples from an AIDS patient who had been treated with zidovudine for 9 months, Phylogenetic analyses showed that a reduction in genetic heterogeneity of the env regions of viruses present in the proviral blood population occurred during therapy, and this coincided with an increased pol gene heterogeneity. Differences were observed in different organs obtained post mortem for both the env and pol coding regions. The cardiac blood proviral population consisted mainly of variants which possessed sequences containing mutations at position 215 of the pol gene, associated with drug resistance. By contrast, the brain population consisted entirely of zidovudine sensitive genotypes, and this organ also harboured variants with genetically distinct env sequences. The lymph tissues obtained after death held more diverse proviral env and pol populations, containing both zidovudine sensitive and resistant genotypes.
Introduction
Extensive temporal and topographical genetic variations are observed in human immunodeficiency virus type 1 (HIV-1) populations in different individuals and also in those present within the same individual Epstein et al., 1991 ; Delassus et al., 1992; Ball et al., 1994) . The structural genes of HIV-1 differ in their levels of genetic variation, with the gag and pol genes being more conserved than the env gene (Myers et al., 1994) . However, the genetic heterogeneity observed within the env gene does not occur randomly across the whole gene but is mainly located in five hypervariable regions (V l-V5) of the gp 120 coding region. The variable regions of env are rapidly evolving, although the rate and The nucleotide data have been deposited in GenBank under accession numbers U45330-U45421. direction of change are not uniform. Phenomena such as G~A hypermutation (Meyerhans et al., 1989; Vartanian et al., 1991) , and convergent and divergent evolution (Holmes et al., 1992) are frequently observed. Phylogenetic analyses of sequence turnover within env suggest that the evolutionary trends might in part be caused by positive selective pressure Holmes et al., 1992) . Both humoral and cell-mediated immune selection and constraints in cell tropism are potential causes for sequence change within the hypervariable (V) regions of env. The V1/V2, V3 and V4 regions as well as conserved region 4 (C4), located between V4 and V5, have all been shown to contain linear or conformationally sensitive neutralizing antibody or cytotoxic T cell (CTL) determinants (Javaherian et al., 1989; Thali et al., 1994; Kayman et al., 1994) . In addition, mutations within several of these regions, in particular V3 and V1/V2, have been shown to affect cytopathogenicity and cell tropism (Takeuchi et al., 1991; Westervelt et at., 1992; Fouchier et al., 1992; Groenink et al., 1993) .
Selection of drug resistant virus variants during prolonged anti-HIV therapy with zidovudine (AZT) is frequently encountered (Larder, 1994 
Methods
Patient samples. Sequential PBMC samples (E21PBL and E21 aPBL) and samples of cardiac blood, lymph node, spleen, bone marrow and brain taken at necropsy (E21b), were obtained from a symptomatic AIDS patient. The peripheral blood samples were obtained 13 months (E21) and 10 months (E21a) prior to death. Zidovudine therapy was administered during the terminal stages of disease, and was started 1 month after the second sequential blood sample E21a was obtained, and terminated after 9 months duration, 2 months before death.
Nucleic acid extractions. DNA was extracted from Ficol~Hypaque purified PBMCs or organ samples as described previously (Ball et al., 1994) using either the sarcosyl-proteinase K phenol method of Simmonds et al. (1990a) or a commercially available extraction kit (Stratagene). RNA was extracted from plasma derived from the cardiac blood and used as template in a reverse transcription procedure to produce cDNA, as described previously (Ball et al., 1994) .
PCR. The following env (e) and pol (p) primers described by Simmonds et al. (1990a, b) , Ball et al. (1994) and Sheehy & Desselberger (1993) were used in nested primer reactions. The env andpolcoordinates correspond to those of H IV-1 HXB2 (Myers et al., 1994) : 401 (e, sense, 6539, 5' GAG GAT ATA ATC AGT TTA TGG 3'); 306 (e, sense, 7009, 5' TGG CAG TCT AGC AGA AGA AG 3'); 307 (e, antisense, 7331, 5' CTG GGT CCC CTC CTG AGG 3'); 502 (e, sense, 7360, 5' GGG GAA TTT TTC TAC TGT AAT 3'); 503 (e, antisense, 7665, 5' CTT CTC CAA TTG TCC CTC ATA 3'); 504 (e, antisense, 7814, 5' CCA TAG TGC TTC CTG CTG CT 3'); RVL8 (p, sense, 1877, 5' GTT GAC TCA GAT TGG TTG CAC 3'); WHO1 (p, sense, 1947, 5' CCA GGA ATG GAT GGC CCA 3'); WHO2 (p, antisense, 3578, 5' CCT GAT TCC AGC ACT GAC 3'); NS12 (p, antisense, 3877, 5' GTT TCC TGC CCT GTC TCT GCT 3').
The amplification of single DNA/cDNA molecules was carried out using methods described previously (Ball et al., 1994) . Amplification of a portion of the gpl20 coding region encoding all the hypervariable regions of env was achieved using the primer pair 401 and 504 in a first round reaction. Aliquots (1 tal) of this then served as template for separate second round reactions using primer pairs 306 and 307 and 502 and 503 to amplify the V3 and V4/C4/V5 regions, respectively, from the same initial target molecule.
For amplification of the RT coding region, the outer primer pair RVL8 and NS12 was either included with the env primers 401 with 504 or used alone in first round amplifications of the end-point titrated DNA samples. Aliquots (1 gl) of the amplification products were then used as template in the second round reactions using primers WHO1 and WHO2.
Discriminative PCR amplification of zidovudine sensitive and resistant genotypes. Samples of DNA containing approximately 50 molecules of HIV-1 DNA, as determined by end-point titration, were used as templates in first round amplifications using primers RVL8 and NS 12; 1 gl of this was then used as template in second round reactions using primers designed to discriminate between variants containing mutations at position 215 which confer zidovudine resistance (ATG TTT TTT GTC TGG TGT GAA) or sensitivity (ATG TTT TTT GTC TGG TGT GGT) (the discriminative nucleotides are shown in bold type; Larder, 1994) .
PCR product sequencing. Positive single molecule PCR amplification products were identified using ethidium bromide stained agarose gel electrophoresis and purified using the commercially available Isogene kit (Perkin Elmer Cetus). Purified V3-and RT-specific PCR products were used as templates in sequencing reactions using components of the Sequenase version 2 kit (USB) in the presence of E. coli single-stranded DNA binding protein (Ball & Desselberger, 1992 ) and only two labelling nucleotides (Tsang & Bentley, 1989; Ball et al., 1994) .
Determination of the V4/V5 sequences was achieved using components from commercially available Taq polymerase cycle sequencing kits (Promega or USB). Sequencing products were labelled directly using 0-5 lal of [35S]dATP (1000 Ci/mmol) and the samples were subjected to 35 cycles consisting of 94 °C for 45 s, 60 °C for 45 s and 72°C for 1 min. Sequencing products were analysed by ureapolyacrylamide gei electropboresis followed by autoradiography.
Sequence determination of the RT gene-specific amplification products was carried out using the primer WHO1 and sequencing primer NSll (2467, 5' TGT ATG TAG GAT CTG ACT 3').
DNA sequence analysis. Nucleotide sequences were aligned using CLUSTAL W, with minor manual adjustment. Pairwise distances among sequences were estimated by the 2-parameter method of Kimura (1980) to adjust for superimposed substitutions; any site containing a deletion in any sequence in the alignment was excluded. Phylogenetic trees were constructed from the matrix of pairwise distances using the neighbour-joining method (Saitou & Nei, 1987) . The stability of the tree topologies was examined using 1000 bootstrap resamples. These methods were implemented using CLUSTAL W.
Results

Sequence analysis of regions of env
Single proviral or plasma RNA-derived cDNA molecules, obtained at end-point dilution, were PCR amplified, then nucleotide sequences for the V3 and V4/C4/V5 regions of env located on the same molecule were determined using a direct-sequencing procedure. The deduced amino acid sequences are presented in Fig. 1 . The majority of the sequence variation was located in the hypervariable regions, and compared to other studies Wolinsky et al., 1992) . The frequency of nucleotide insertions and deletions present in the E2 l-E21 b dataset was low. As described previously (Ball et al., 1994) , variants containing V3 loop apical motifs GPGR and GPXGPGS were present in the peripheral blood proviral populations obtained before death. Variants containing the unusual motif GPXGPGS were absent from the cardiac blood proviral population obtained post mortem but were frequently present in sequences obtained from the lymph node and bone marrow samples obtained after death. The brain contained a distinct and homogeneous population for all regions analysed and also possessed an unusual V3 apical motif of GPGG. The V5 sequences determined for the cardiac blood proviral population were more homogeneous than the sequential blood samples obtained before death and the lymph node and bone marrow samples obtained post mortem; however, similar heterogeneity was observed for the V4 regions. The C4 region was highly conserved at the amino acid level, although one polymorphic site was identified at position 128. Much variation was observed in the positions and numbers of potential N-linked glycosylation sites in V4/V5 compared to V3. Altered glycosylation patterns arose because of mutations of asparagine residues or by mutation of the serine or threonine residue in the third position of the glycosylation site (NXT or NXS). The unique potential glycosylation site within C4 (position 121) was conserved throughout the entire dataset. 
Phylogenetic analyses of the env regions
To examine the temporal and spatial differences observed in the E2 l-E21 b dataset, the unique nucleotide sequences were used to construct phylogenetic trees. For rooting purposes, the Haitian isolate RF was used as an outgroup; this has previously been shown to form a natural outgroup for subtype B isolates (Sharp et al., 1994) . Three distinct phylogenetic groups were found for the V3 analyses (Fig. 2 a) , and the major clades were identifiable according to the V3 apical motif (Ball et al., 1994) . To assess whether the V4/C4/V5 regions also fell into these three distinct groups a similar analysis of the V4/C4/V5 region was carried out (Fig. 2b) . Although the majority of sequences containing the phylogenetically distinct sequences with the motif GPXGPGS also formed a unique group in the V4/C4/V5 analysis, some of the variants containing this motif could be found grouped with viruses containing the usual GPGR V3 motif. Upon visual inspection of these sequences, there was no evidence of recombination events. Finally, the brain variants formed a distinct group for all regions analysed. 
Sequence analysis of regions of the RT genes of single molecules obtained from the E21-E21b samples
Nested primer amplification of the RT region, encompassing amino acids 24-261, was carried out, and the nucleotide sequences of two regions encompassing amino acids 24-84 and 202-261 were determined. The deduced amino acid sequences are presented in Fig. 3 . The frequency at which each sequence occurred in the sample is shown at the 3' end of the sequences. The amount of amino acid heterogeneity observed was limited and no sample-specific amino acid changes were observed. The amino acids present at specific codons previously shown to confer zidovudine resistance (Larder, 1994) are summarized in Table 1 . All the proviral molecules obtained from the sequential peripheral blood samples taken before (E21), or shortly after (E21a) initiation of therapy contained zidovudine sensitive genotypes, as predicted from the amino acids present at positions 41, 67, 70, 216 and 219. Sequences obtained from the cardiac blood proviral population, obtained approximately 9 months after onset of therapy, were either resistant, as predicted by mutations at 215 TM ~ Tyr or 215 Thr" Tyr plus 41Met-~ Leu, or contained an unusual mutation at position 215 Thr'ASp. One molecule obtained from the cardiac blood (d) also contained a mutation at position 41 from methionine ~ isoleucine. The phenotypes conferred by these two mutations are as yet unknown. One molecule from the bone marrow also contained the unusual mutation at position 215 T~r-~A~p. By contrast, the brain population consisted of entirely zidovudine sensitive genotypes. The bone marrow and lymph node contained not only zidovudine resistant variants, as indicated by amino acids at positions 215 and 41, but also zidovudine sensitive genotypes at frequencies of 1/14 and 5/14 molecules, respectively.
Verification of temporal and topographical differences of zidovudine sensitive and resistant genotypes
The differences in the distribution of RT genotypes observed in the sequences obtained from samples E21-E21b were verified using discriminative PCR specific for codon 215 (Fig. 4) . Samples of DNA from the two sequential peripheral blood samples obtained prior to death (E21 and E21a) and the brain sample obtained at autopsy contained amplification products corresponding to zidovudine sensitive genotypes. The cardiac blood proviral sample contained exclusively zidovudine resistant genotypes, whilst the lymph node, spleen and bone marrow samples contained both zidovudine sensitive and resistant genotypes. This suggests that the results found by direct sequencing are representative of the proviral population.
Changes in the genetic heterogeneity of the pol and env regions
The mean nucleotide distances within each sample set were determined for the V3, V4/C4/V5 and RT nucleotide sequences (Table 2) , and, as expected, the env regions were in general less homogeneous than pol. The Fig. 3 . Deduced amino acid sequences of two regions, amino acids 24-84 (a) and 202-261 (b) , of the HIV-1 RT coding region derived from single proviral DNA molecules obtained from sequential blood and autopsy samples of patient E21-E21b. The amino acid numbering is in keeping with that of the HIV-I sequence HXB2 (Myers et al., 1994) . Amino acids previously shown to be involved in zidovudine resistance are underlined. The frequency with which that sequence was found in that sample is shown at the end of the sequences. Identical single molecule descriptors (roman numerals) indicate sequence identity for both of the RT regions analysed. *indicates premature stop mutations. level of variability within the env region of provirus obtained from autopsy cardiac blood (E21b) was low, compared to the sequential blood samples obtained before death (E21, E21a). This correlated with an increase in the variability of the pol coding region in the same samples, and this occurred following zidovudine therapy. However, the increase in genetic heterogeneity was not solely caused by the acquisition of zidovudine resistant mutants as distances generated in analyses where the five zidovudine resistance codons were either included or omitted were comparable. The proviral population in the brain was the most homogeneous for all regions analysed.
Discussion
Sequence analysis of regions of env
Amplification of regions of gp120 obtained from single molecules o f H I V -1 c D N A / D N A allowed direct comparisons to be made of sequence changes observed in the V3 and the V4/C4/V5 regions of viruses present in sequential blood and autopsy specimens. The salient points obtained from the V3 analyses have been discussed elsewhere (Ball et al., 1994) . Briefly, topographical and temporal variation of the V3 regions was observed. Mutations occurring within the V3 sequences, and particularly changes occurring around the loop apex, might affect immune recognition (Javaherian et al., 1989; Takahashi et al., 1989) , cell tropism and cytopathogenicity (Takeuchi et al., 1991; Fouchier et al., 1992) . Conformationally sensitive epitopes encompassing regions of the CD4 binding domain, including the C4 region, and epitopes involving the V2, V3 and V4 regions have been described (Thali et al., 1994; McKeating et al., 1993 ; K a y m a n et al., 1994). The C4 regions of the E2 l -E 2 l b variants were highly conserved, although immune escape might have been mediated by conformational changes induced by the sequence changes observed in the variable regions, Variation of N-linked glycosylation sites of the V4 and V5 regions might influence immune recognition by altering or masking epitopes, or by modification of the tertiary structure of the molecule (Li et al., 1993) .
Analyses of R T coding regions
Zidovudine resistant genotypes, as determined by muta-tions at position 215 or positions 215 and 41, were present in some of the samples obtained post mortem, although topographical differences in the distribution of zidovudine sensitive and resistant genotypes were observed. This uneven distribution of zidovudine genotypes was further verified by using primer-discriminative PCR. In addition to mutations previously associated with zidovudine resistance, three sequences contained the mutation 215 ~hr~Asp, the phenotype of which is unknown. Zidovudine sensitive genotypes persisted in the brain of this patient, and this might suggest that zidovudine did not reach inhibitory concentrations within this organ due to restricted transport across the blood brain barrier or from the cerebro-spinal fluid to the brain (Klecker et al., 1987; Terasaki & Pardridge, 1988; Lupia et al., 1993) . The presence of zidovudine resistant genotypes in the cerebro-spinal fluid has been reported (di Stefano et al., 1993) , although at present it is not clear whether this population is representative of that found in the brain. Persistence in the brain, and to some extent in lymph nodes and bone marrow, of zidovudine sensitive variants might reflect the cell types infected. Cells of monocyte/macrophage origin are the most likely target for infection in the brain (Gartner et al., 1986) , whilst in the lymph nodes significant numbers of monocytic cells are also infected (Embretson et al., 1993; Pantaleo et al., 1993) . In vitro tests have shown that zidovudine is ineffective against chronically infected monocyte cultures (Crowe et al., 1989) and this might be due to inefficient phosphorylation (Hao et al., 1988; Balzarini et al., 1988) . The patient described here received therapy at the terminal stages of disease, and as dissemination of virus to the central nervous system occurs late in infection (Donaldson et al., 1994) , initiation of therapy earlier in the disease course might result in the the appearance of resistant genotypes in the brain. Finally, the possibility exists that resistance might be conferred by mutations at amino acids other than the five identified positions (Sheehy & Desselberger, 1993) .
Nature of sequence change in regions of env and RT
Only four inactivating mutations out of a total of approximately 78 000 nucleotides sequenced (a frequency of approximately 5 x 10 -~) were present in the E21-E21b sequences. This estimate is the same as that calculated by Balfe et al. (1990) , 3-fold lower than that reported by Oram et al. (1991) and approximately 10-fold lower than that given by Meyerhans et al. (1989) . One possible reason for this discrepancy might be that the results obtained by Balfe et al. (1990) and the data presented here were derived from directly sequenced PCR products derived from single DNA/cDNA molecules whilst Oram et al. (1991) and Meyerhans et al. (1989) sequenced cloned PCR products.
Evolution of the env and pol genes
Variants containing the unusual V3 GPXGPGS apical motifs and zidovudine sensitive variants both disappeared from the peripheral blood proviral population but persisted in the lymph node and bone marrow. Several mechanisms might explain this, for example host immune or viral cytopathic determinants might have selected against production of variants possessing the unusual apical motif, and during therapy zidovudine resistance developed in variants with altered env characteristics. Alternatively, zidovudine therapy selected for a pre-existing zidovudine resistant population which possessed different env sequences. Previous research has shown that variants containing the mutation 70 Lys ~Arg, which confers low level resistance and is the first mutation associated with resistance (Larder, 1994) are found in pre-treatment genetic pools Najera et al., 1995) . Therefore, a conceivable scenario is that therapy initially selects for a pre-existing subpopulation (perhaps located in lymph tissue) which contains the 70 Lys ~ Arg mutation, then, under continued drug selection these variants would eventually gain higher levels of resistance (Larder, 1994) . Selective pressures such as cell tropism or immune escape would drive concurrent changes within other genes, for example env, resulting in complex evolutionary patterns for each of the coding regions. The dynamics of these sequence changes, particularly that observed within the lymph tissue and plasma, would be very rapid (Ho et al., 1995; Wei et al., 1995; Nowak et al., 1995) . Therefore, in the patient detailed here, it is conceivable that dual selective pressures have selected for variants, located in the peripheral circulation, that possess unique pol and env sequences. Persistence of variants within the bone marrow and lymph nodes might represent a reservoir of latent virus which upon favourable conditions (e.g. cessation of therapy or changing immune status) might re-infect the peripheral blood; re-emergence of sensitive genotypes, in plasma following cessation of therapy, has been reported (Albert et al., 1992) . The co-existence of such diverse populations within these tissues might also provide ideal conditions for recombination events as have recently been shown to occur in vitro between viruses exhibiting resistance to different antiretrovirals (Gu et al., 1995) .
These studies have provided further evidence that topographical differences in the distribution of HIV-I populations exist and that selective pressures exerted on one gene might, in part, be associated with sequence changes observed in other genes. The apparent persistence of drug sensitive genotypes in lymph tissue and brain has important implications for the design of appropriate regimens of drug administration.
